A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
Phase 1
Completed
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- BeiGene USA, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT03150862
- Locations
- 🇺🇸
Center For Neurosciences, Tucson, Arizona, United States
🇺🇸UCLA, Los Angeles, California, United States
🇳🇱Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
© Copyright 2025. All Rights Reserved by MedPath